|
|
 |
|
Viewing report
|
|
|
|
Interferons - State-of-the-Science and Strategic Opportunities
BioStrategy, Jan 2000, Pages: 25
The world market for interferons was valued at US$2.3 billion in 1999. Interferon alfa accounted for 72% of the market mainly through the antiviral indications for hepatitis. Interferon beta, which was the fastest growing segment of the market, accounted for 24% by the end of the year.
The interferon market is application dependent with different indications approved in different markets. The impact of launch of interferon in a market is not as important as the impact of its approval for a main-line indication.
This makes interferons a multiple niche market accessible to small players. Although the market is currently controlled by large companies, the success of the launch Avonex by Biogen symbolizes the ease with which a small company can exploit a biopharmaceutical niche based on an indication approval.
The success of interferons symbolize the success of hope and scientific hype over reason. The product has a high side effect profile and a low efficacy profile. However, performing clinical trials in small number of patients can yield statistically creative results that lead to an approval for a relapsing disease like hairy cell leukemia or MS. Develop several small niches in different areas and you have a product generating hundreds of millions of dollars every year.
Interferons, State-of-the-Science and Strategic Opportunities is a strategic business report that assesses both the technology status and the competitive landscape of the world interferons market. The report examines both the US and the European markets in detail, profiles leading products and companies and offer revenue forecasts to the year 2005. The report assesses the market attractiveness and potential and evaluates different options for market entry.
Customers who bought this item also bought
Competitor Analysis: Interferon
Commercial Perspectives: Pegylated Interferons - Leading the Way in HCV Therapy?
Pipeline Perspectives: Hepatitis B and C - Antivirals Challenge the Interferons?
Pipeline Perspectives: Hepatitis B and C - Antivirals Challenge the Interferons?
Hematological Malignancies: Companies Target Niche Indications to Facilitate Market Entry
New Pegylated Interferons: Assessing the Impact of the New Longer Acting Interferons on the Hepatitis C Market
Thrombolytics: State-of-the-Science and Strategic Opportunities
Insulin: State-of-the-Science and Strategic Opportunities
Pipeline/Commercial Insight: Supportive Care In Oncology - Significant Growth Opportunities Exist In New Supportive Care Indications
rTPAs State-of-the-Science and Strategic Opportunities
Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs
Erythropoietin State-of-the-Science and Strategic Opportunities
|
|
|
|
